Search clinical trials for: LY3437943

Total 23 results

Eli Lilly and Company

Completed

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Healthy | Renal Insufficiency

United States
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Type 2 Diabetes | CKD | Overweight or Obesity

United States, Italy, United Kingdom, Spain, Canada
Eli Lilly and Company

Completed

A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Active, not recruiting

A Study of LY3437943 in Healthy Participants With a High Body Mass Index

Healthy

United States
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)

Obesity | Overweight | Osteo Arthritis Knee

United States, Canada, Spain, Australia, Mexico, United Kingdom
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)

Obesity | Overweight | Obstructive Sleep Apnea | Type 2 Diabetes

Australia, United States, Mexico, Spain, India, Brazil, Romania, Taiwan, Argentina
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)

Cardiovascular Diseases | Obesity

United States, Australia, Mexico, Spain, Canada, Hungary, Argentina, Puerto Rico, Poland, Slovakia
Eli Lilly and Company

Not yet recruiting

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Diabetes Type 2

United States, India, Mexico, Puerto Rico
Eli Lilly and Company

Completed

A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices

Healthy

United States
Eli Lilly and Company

Recruiting

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Obesity

United States
Eli Lilly and Company

Completed

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Obesity | Overweight

China
Eli Lilly and Company

Completed

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Healthy

United States
Eli Lilly and Company

Completed

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Obesity | Overweight

United States, Puerto Rico
Eli Lilly and Company

Recruiting

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Hepatic Insufficiency | Healthy

United States
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 Diabetes

United States, United Kingdom, Argentina, Puerto Rico
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)

Obesity | Overweight | Knee Osteoarthritis | Obstructive Sleep Apnea | Knee Pain Chronic

United States, Australia, Canada, Hungary, Mexico, India, Spain, United Kingdom, Taiwan, Romania, Brazil, Poland
Eli Lilly and Company

Not yet recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Overweight and Obesity

United States, Canada, Australia, Germany, Mexico, Argentina, Brazil, Hungary, Austria, India, Poland, Slovakia, Spain, Netherlands, Turkey, Czechia, United Kingdom, Denmark, Puerto Rico, France, Israel
Eli Lilly and Company

Completed

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of LY3437943 in Participants With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Argentina, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Overweight

United States
Eli Lilly and Company

Completed

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Obesity

United States

Search clinical trials for: LY3437943

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations